Medtronic plc (MDT) operating KPIs
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)
Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%
Medtronic respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) ($M)
Reorganized into Acute Care & Monitoring, Endoscopy, and Renal/Ventilator exit starting FY2024Q1.
Latest, FY2023
2,770
Period ended Apr 30, 2023
Change on a year earlier
-10.1%
3,081 in FY2022
History
7 years
Since FY2017
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Apr 30, 2023 | 2,770 | -10.1% | Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗ |
| FY2022 | Apr 30, 2022 | 3,081 | -6.6% | Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗ |
| FY2021 | Apr 30, 2021 | 3,298 | +16.2% | Medtronic SEC 8K_EARNINGS — FY2022Q4 (filed 2022-05-26) ↗ |
| FY2020 | Apr 30, 2020 | 2,839 | +4.2% | Medtronic SEC 8K_EARNINGS — FY2021Q4 (filed 2021-05-27) ↗ |
| FY2019 | Apr 30, 2019 | 2,725 | 0.0% | Medtronic SEC 8K_EARNINGS — FY2020Q4 (filed 2020-05-21) ↗ |
| FY2018 | Apr 30, 2018 | 2,725 | -42.9% | Medtronic SEC 8K_EARNINGS — FY2019Q4 (filed 2019-05-23) ↗ |
| FY2017 | Apr 30, 2017 | 4,774 | – | Medtronic Form 10-K — FY2019 (filed 2019-06-21) ↗ |
Breakdown
What makes up respiratory, gastrointestinal & renal (legacy through fy2023q4) — worldwide revenue ($m)
- Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Organic Revenue Growth YoY (%)-4.8% · FY2023
- Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Foreign Currency Impact ($M)-131 · FY2023
- Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Reported Revenue Growth YoY (%)-10.1% · FY2023
- Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Revenue ($M)1,418 · FY2023
Cite this data
StockData. (2026). Medtronic Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) ($M), annual FY2017–FY2023 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/ms-rgr-leg-ww-rev
See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.